Bioventus (BVS) Accumulated Expenses (2020 - 2026)

Bioventus (BVS) has 7 years of Accumulated Expenses data on file, last reported at $101.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 2.08% year-over-year to $101.1 million; the trailing twelve-month figure through Mar 2026 stood at $101.1 million (down 2.08% YoY), and the FY2025 full-year result was $130.2 million, down 4.15% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $101.1 million, down from $130.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $146.8 million in Q3 2022 and bottomed at $101.1 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $119.4 million (2025), against an average of $121.3 million.
• The widest annual swing landed in 2022, when Accumulated Expenses soared 39.44%; it then retreated 18.8% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $111.6 million in 2022, then climbed by 7.37% to $119.8 million in 2023, then advanced by 13.43% to $135.9 million in 2024, then fell by 4.15% to $130.2 million in 2025, then dropped by 22.35% to $101.1 million in 2026.
• The last three Accumulated Expenses figures came in at $101.1 million (Q1 2026), $130.2 million (Q4 2025), and $119.4 million (Q3 2025), per Business Quant data.

Peer Comparison